Antimicrobial Resistance After the COVID-19 Pandemic
July 1, 2024
A post-pandemic warning from CDC
Antimicrobial resistance (AR) was a serious threat before COVID-19; the pandemic strained the very infection-prevention practices that keep resistant organisms in check. In July 2024, the Centers for Disease Control and Prevention (CDC) published updated burden estimates for seven antimicrobial-resistant pathogens commonly associated with U.S. health care settings, covering data from 2021 and 2022 and comparing them with 2019 baselines.
For students entering hospitals where isolation precautions, stewardship rounds, and contact tracing are everyday realities, the update is a reminder that public health surveillance directly informs bedside practice. Resistance is not an abstract microbiology lecture—it reflects staffing, device use, antibiotic exposure, and the integrity of transmission-based precautions.
Which pathogens CDC tracked
CDC’s fact sheet focuses on seven organisms: carbapenem-resistant Enterobacterales (CRE); carbapenem-resistant Acinetobacter; Candida auris (C. auris); methicillin-resistant Staphylococcus aureus (MRSA); vancomycin-resistant Enterococcus (VRE); extended-spectrum beta-lactamase (ESBL)-producing Enterobacterales; and multidrug-resistant (MDR) Pseudomonas aeruginosa.
These pathogens appear in intensive care units, long-term acute care, and transfer networks. CRE and carbapenem-resistant Acinetobacter limit last-line antibiotic options. ESBL-producing Enterobacterales and MDR Pseudomonas complicate empiric therapy for pneumonia and device-associated infections. VRE and MRSA remain familiar foes on wards and in surgical services.
C. auris is a yeast that can spread in health care facilities, is often resistant to antifungals, and can cause severe illness. CDC distinguishes clinical cases identified when routine care specimens test positive—an important detail for understanding surveillance trends versus colonization screening practices.
Key findings from 2021–2022
CDC previously reported increased burden in 2020 in its COVID-19 impact report. The 2024 update extends the timeline. Six bacterial antimicrobial-resistant hospital-onset infections—CRE, carbapenem-resistant Acinetobacter, MRSA, VRE, ESBL-producing Enterobacterales, and MDR Pseudomonas—increased by a combined 20% during the pandemic compared with the pre-pandemic period, peaking in 2021. In 2022, rates for all but one of these pathogens (MRSA) remained above pre-pandemic levels.
Reported clinical cases of C. auris increased nearly five-fold from 2019 to 2022. That trajectory alarms infection preventionists because outbreaks can persist on surfaces and equipment, requiring aggressive environmental measures and coordination among facilities.
CDC attributes part of the 2020–2021 surge to pandemic pressure: longer hospital stays (including among patients with COVID-19), challenges implementing infection prevention and control, and inappropriate antibiotic use. CDC also notes that as the pandemic continued, clinicians and public health professionals took aggressive action, supported by American Rescue Plan Act funding to state HAI/AR programs, antibiotic stewardship programs, and CDC’s Antimicrobial Resistance Laboratory Network—helping reduce AR burden from its 2021 peak.
Why medical students should care
Students influence antibiotic prescribing even when they do not order therapy independently. Questions like “Could this be viral?” or “Do we have culture data?” reinforce stewardship culture. Hand hygiene, PPE diligence, and respectful reminders when lapses occur protect vulnerable neighbors on the unit.
Rotations also expose learners to transfer patterns—patients moving from smaller hospitals to tertiary centers can import resistant organisms. Understanding CRE or C. auris epidemiology helps students appreciate why admission screens and contact precautions feel burdensome yet necessary.
Stewardship, surveillance, and policy
CDC’s 2013 and 2019 AR Threats Reports guided U.S. policy and investments. The 2021–2022 release is a interim fact sheet; CDC plans a broader electronic update in 2026 with estimates for at least 19 threats, with refreshed estimates at least every two years thereafter. Data quality matters for allocating prevention funds and evaluating interventions.
Students interested in health policy or rural health should note that resistance and access interact: delayed care, nursing shortages, and supply chain gaps can worsen outcomes. Arizona’s diverse urban and rural delivery systems mirror national patterns of variability.
Looking ahead
Progress is possible when hospitals reinvest in core infection prevention, align antibiotics with microbiology, and participate in public health reporting. The 2022 MRSA exception—rates not above pre-pandemic levels while other pathogens remained elevated—shows that targets differ by organism and setting.
Trainees who treat antimicrobial resistance as a systems problem—linking lab turnaround, nursing workload, environmental services, and prescribing habits—will be better prepared for quality-improvement teams and for honest conversations with patients about why antibiotics are not always the answer.
Infection prevention as a shared skill
Central-line and catheter-associated infection bundles, sterile technique during procedures, and timely device removal all reduce the exposure that selects for resistant organisms. Students should treat audits and checklists as learning tools, not bureaucratic noise. When units are understaffed, shortcuts tempt even experienced teams; speaking up about unsafe ratios is part of protecting patients from secondary infections.
Public health reporting delays can mask local outbreaks until patterns appear in antibiograms. Microbiology rounds connect bench data to empiric choices—attend when your service offers them. CDC’s commitment to biennial burden updates means the 2021–2022 fact sheet is a waypoint, not the final word; staying current will remain part of lifelong practice.
Antibiotic stewardship committees review broad-spectrum use, duration, and IV-to-oral switches; students can prepare by reading your hospital’s antibiogram before presenting patients. Document allergy histories accurately to avoid unnecessary alternative regimens that drive resistance. When patients request antibiotics for viral syndromes, use CDC-aligned talking points that acknowledge symptoms while explaining why withholding drugs protects the patient and community.
Finally, remember that AR threats intersect with global travel and long-term care transfers. A patient colonized with an organism listed in CDC’s fact sheet may be asymptomatic yet require precautions; read your facility’s policy and ask infection prevention staff when unsure rather than guessing isolation categories from memory alone.
Share CDC updates during journal club or noon conference so your team discusses local antibiogram trends alongside national surveillance releases.